{"entity":{"id":"adc-plus-io","kind":"pairing","name":"ADC + checkpoint inhibitor","aka":[],"tldr":"An ADC kills tumour cells in a way that alerts the immune system; a checkpoint inhibitor lets the immune system finish the job.","summary":"Proven in urothelial cancer (EV-302: enfortumab vedotin + pembrolizumab, OS HR 0.47) and TNBC (ASCENT-04: sacituzumab govitecan + pembrolizumab, PFS HR 0.65, approved 2026). TROPION-Breast05 (Dato-DXd + durvalumab) and multiple lung trials follow. Overlapping pneumonitis risk with DXd ADCs needs care.","asOf":"2026-09-04","links":[{"label":"ClinicalTrials.gov NCT04223856: EV-302 / KEYNOTE-A39","url":"https://clinicaltrials.gov/study/NCT04223856"},{"label":"ClinicalTrials.gov NCT05382286: ASCENT-04 / KEYNOTE-D19","url":"https://clinicaltrials.gov/study/NCT05382286"}],"tags":[],"related":[],"cancers":["urothelial","tnbc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["enfortumab-vedotin","sacituzumab-govitecan","pembrolizumab"],"companies":[],"institutions":[],"pathways":["cgas-sting"],"terms":[],"trials":["ev-302","ascent-04","tropion-breast05"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"a":"adc","b":"checkpoint-inhibitor","rationale":"TOP1 and tubulin payloads induce immunogenic cell death, cGAS-STING activation, and antigen release; ADCs also deplete immunosuppressive myeloid cells. PD-1 blockade converts the resulting T-cell priming into durable control.","evidence":"Phase 3 positive in two tumour types; multiple ongoing.","pairingType":"combination"},"route":"/pairings/adc-plus-io/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"pathway":[{"id":"cgas-sting","kind":"pathway","name":"cGAS-STING innate sensing","route":"/pathways/cgas-sting/"}],"trial":[{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/"},{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/"},{"id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"idea":[{"id":"idea-fund-combination-patent-pool","kind":"idea","name":"An oncology patent pool for combination trials across companies","route":"/ideas/idea-fund-combination-patent-pool/"},{"id":"idea-neoadjuvant-adc-io","kind":"idea","name":"Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC","route":"/ideas/idea-neoadjuvant-adc-io/"}]}}